Vanguard Group Inc. Has $44.52 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Vanguard Group Inc. increased its shareholding in Xeris Biopharma by 2.7%, acquiring an additional 210,581 shares, bringing its total ownership to approximately 5.19% of the company, valued at $44.5 million.
• Numerous institutional investors, including Millennium Management and Essex Investment Management, have significantly boosted their stakes in Xeris Biopharma, highlighting strong hedge fund interest in the company.
• Xeris Biopharma recently reported earnings of ($0.01) per share, beating estimates, with a quarterly revenue of $67.71 million, exceeding expectations of $64.58 million.

Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,109,644 shares of the company's stock after purchasing an additional 210,581 shares during the period. Vanguard Group Inc. owned approximately 5.19% of Xeris Biopharma worth $44,522,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its stake in Xeris Biopharma by 92.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after buying an additional 14,986 shares in the last quarter. Millennium Management LLC increased its holdings in Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after buying an additional 502,853 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Xeris Biopharma in the fourth quarter worth approximately $47,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the fourth quarter valued at approximately $45,000. Finally, CWM LLC grew its holdings in Xeris Biopharma by 79.3% during the first quarter. CWM LLC now owns 66,972 shares of the company's stock valued at $368,000 after purchasing an additional 29,614 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Trading Down 1.1%

XERS stock traded down $0.09 during midday trading on Thursday, hitting $7.90. The stock had a trading volume of 1,706,428 shares, compared to its average volume of 3,586,782. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -37.62 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.48 and a 52 week high of $8.02. The stock has a 50-day simple moving average of $5.81 and a 200 day simple moving average of $4.96.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the completion of the transaction, the director directly owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Mcculloch purchased 25,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider directly owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 6.47% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Leerink Partners raised their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 19th. Oppenheimer raised their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, HC Wainwright started coverage on shares of Xeris Biopharma in a research note on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.08.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.